UY34350A - Derivados de pirazolquinolinona, su preparación y su uso terapéutico. - Google Patents
Derivados de pirazolquinolinona, su preparación y su uso terapéutico.Info
- Publication number
- UY34350A UY34350A UY0001034350A UY34350A UY34350A UY 34350 A UY34350 A UY 34350A UY 0001034350 A UY0001034350 A UY 0001034350A UY 34350 A UY34350 A UY 34350A UY 34350 A UY34350 A UY 34350A
- Authority
- UY
- Uruguay
- Prior art keywords
- pirazolquinolinona
- derivatives
- preparation
- therapeutic use
- therapeutic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
- C07C229/54—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C229/56—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring with amino and carboxyl groups bound in ortho-position
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
- C07C229/54—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C229/62—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring with amino groups and at least two carboxyl groups bound to carbon atoms of the same six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
- C07C237/30—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
- C07F5/02—Boron compounds
- C07F5/04—Esters of boric acids
Abstract
La invención se refiere a compuestos que corresponden a la fórmula (I) en la que R1, R2 y R3 son como se define en la reivindicación 1, como también a los procedimientos para prepararlos y a su uso terapéutico.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11306217.8A EP2573073B1 (en) | 2011-09-26 | 2011-09-26 | Pyrazoloquinolinone derivatives, preparation thereof and therapeutic use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
UY34350A true UY34350A (es) | 2013-04-30 |
Family
ID=46880738
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001034350A UY34350A (es) | 2011-09-26 | 2012-09-26 | Derivados de pirazolquinolinona, su preparación y su uso terapéutico. |
Country Status (23)
Country | Link |
---|---|
EP (2) | EP2573073B1 (es) |
JP (1) | JP6073328B2 (es) |
KR (1) | KR20140082743A (es) |
CN (1) | CN103958479B (es) |
AR (1) | AR088000A1 (es) |
AU (1) | AU2012314620B2 (es) |
BR (1) | BR112014007193A2 (es) |
CA (1) | CA2847921A1 (es) |
CY (1) | CY1115945T1 (es) |
DK (1) | DK2573073T3 (es) |
ES (2) | ES2527188T3 (es) |
HK (1) | HK1181763A1 (es) |
HR (1) | HRP20150024T1 (es) |
IL (1) | IL231386A (es) |
MX (1) | MX2014003675A (es) |
PL (1) | PL2573073T3 (es) |
PT (1) | PT2573073E (es) |
RU (1) | RU2621037C2 (es) |
SG (1) | SG11201400403SA (es) |
SI (1) | SI2573073T1 (es) |
TW (1) | TWI527815B (es) |
UY (1) | UY34350A (es) |
WO (1) | WO2013045400A1 (es) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103012397B (zh) * | 2011-09-26 | 2017-03-01 | 赛诺菲 | 吡唑并喹啉酮衍生物、其制备方法及其治疗用途 |
JP6042060B2 (ja) * | 2011-09-26 | 2016-12-14 | サノフイ | ピラゾロキノリノン誘導体、その調製および治療上の使用 |
WO2014154586A1 (en) * | 2013-03-25 | 2014-10-02 | Sanofi | Pyrazolonaphthyridinone derivatives as metap2 inhibitors (methionine aminopeptidase type-2) |
BR112015024075B1 (pt) * | 2013-04-05 | 2022-05-03 | Eisai R&D Management Co., Ltd | Compostos de piridinilpirazoloquinolina |
ES2645149T3 (es) * | 2013-04-05 | 2017-12-04 | Eisai R&D Management Co., Ltd. | Sal de derivado de pirazoloquinolina y cristal de esta |
GB201406486D0 (en) | 2014-04-10 | 2014-05-28 | Redx Pharma Ltd | Antibacterial compounds |
GB201516616D0 (en) * | 2015-09-18 | 2015-11-04 | Redx Pharma Plc | Antibacterial compounds |
AU2016325143B2 (en) | 2015-09-18 | 2020-08-13 | Kaken Pharmaceutical Co., Ltd. | Biaryl derivative and medicine containing same |
CN105198888B (zh) * | 2015-10-01 | 2018-03-06 | 湘潭大学 | 2,3a‑二取代‑3H–吡唑并[1,5‑a]吲哚‑4(3aH)‑酮衍生物及其合成方法 |
CN105837557A (zh) * | 2016-05-05 | 2016-08-10 | 青岛辰达生物科技有限公司 | 一种用于治疗ii型糖尿病的阿格列汀的制备方法 |
JP6469272B2 (ja) * | 2017-03-01 | 2019-02-13 | 科研製薬株式会社 | ビアリール誘導体又はその塩からなる医薬 |
CN108721621B (zh) * | 2017-04-14 | 2022-03-01 | 中国科学院上海高等研究院 | 抑制肝纤维化的小分子化合物及应用 |
US11484502B2 (en) | 2017-06-01 | 2022-11-01 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition comprising PDE9 inhibitor |
CN110603039B (zh) | 2017-06-01 | 2023-02-28 | 卫材R&D管理有限公司 | 组合吡唑并喹啉衍生物和美金刚的痴呆治疗剂 |
BR112019023552A2 (pt) | 2017-06-01 | 2020-06-02 | Eisai R&D Management Co., Ltd. | Agente terapêutico para a demência com corpos de lewy contendo derivado de pirazoloquinolina |
IL270395B (en) | 2017-06-01 | 2022-08-01 | Eisai R&D Man Co Ltd | A therapeutic agent for dementia that combines a pyrozoloquinoline derivative and donepezil |
RU2656225C1 (ru) * | 2017-06-22 | 2018-06-04 | федеральное государственное автономное образовательное учреждение высшего образования "Российский университет дружбы народов" (РУДН) | Способ получения производных пирроло[2,1-a]изохинолинов |
PE20201164A1 (es) | 2017-07-11 | 2020-10-28 | Vertex Pharma | Carboxamidas como moduladores de los canales de sodio |
TWI782056B (zh) | 2017-07-14 | 2022-11-01 | 日商鹽野義製藥股份有限公司 | 具有mgat2抑制活性的縮合環衍生物 |
US20210267964A1 (en) | 2018-04-25 | 2021-09-02 | Innate Tumor Immunity, Inc. | Nlrp3 modulators |
CN110845478B (zh) * | 2019-11-25 | 2022-07-08 | 南通大学 | 含1-取代吡啶基-3-三氟甲基吡唑单元的吡唑甲酰肟衍生物的制备和用途 |
WO2021150613A1 (en) | 2020-01-20 | 2021-07-29 | Incyte Corporation | Spiro compounds as inhibitors of kras |
WO2021231526A1 (en) | 2020-05-13 | 2021-11-18 | Incyte Corporation | Fused pyrimidine compounds as kras inhibitors |
WO2022072783A1 (en) | 2020-10-02 | 2022-04-07 | Incyte Corporation | Bicyclic dione compounds as inhibitors of kras |
US11939328B2 (en) | 2021-10-14 | 2024-03-26 | Incyte Corporation | Quinoline compounds as inhibitors of KRAS |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HU167240B (es) * | 1972-06-30 | 1975-09-27 | ||
US3880855A (en) * | 1973-04-16 | 1975-04-29 | Bristol Myers Co | 5,6-DIHYDRO-11-H-pyrimido{8 4,5-b{9 {8 1,4{9 benzodiazepines |
US20050245563A1 (en) * | 2003-05-29 | 2005-11-03 | Millennium Pharmaceuticals, Inc. | Chk-1 inhibitors |
US20080262021A1 (en) * | 2003-11-21 | 2008-10-23 | Novartis Ag | 1H-Imidazoquinoline Derivatives as Prote In Kinase Inhibitors |
US20090233955A1 (en) * | 2004-12-08 | 2009-09-17 | Frazee James S | 1H-Pyrrolo[2,3-B]Pyridnes |
KR20070094957A (ko) * | 2005-01-07 | 2007-09-27 | 아르피다 아게 | 선택된 벤조퓨란 유도체 |
FR2921657A1 (fr) * | 2007-09-28 | 2009-04-03 | Sanofi Aventis Sa | Derives de nicotinamide, leur preparation et leur application en therapeutique |
DE102008027574A1 (de) * | 2008-06-10 | 2009-12-17 | Merck Patent Gmbh | Neue Pyrrolidinderivate als MetAP-2 Inhibitoren |
SI2615089T1 (sl) * | 2010-09-07 | 2016-08-31 | Astellas Pharma Inc. | Spojine pirazolokinolina |
DE102010048374A1 (de) * | 2010-10-13 | 2012-04-19 | Merck Patent Gmbh | Pyrrolidinone als MetAP-2 Inhibitoren |
JP6042060B2 (ja) * | 2011-09-26 | 2016-12-14 | サノフイ | ピラゾロキノリノン誘導体、その調製および治療上の使用 |
-
2011
- 2011-09-26 ES ES11306217.8T patent/ES2527188T3/es active Active
- 2011-09-26 DK DK11306217.8T patent/DK2573073T3/en active
- 2011-09-26 SI SI201130358T patent/SI2573073T1/sl unknown
- 2011-09-26 PL PL11306217T patent/PL2573073T3/pl unknown
- 2011-09-26 PT PT113062178T patent/PT2573073E/pt unknown
- 2011-09-26 EP EP11306217.8A patent/EP2573073B1/en active Active
-
2012
- 2012-09-24 CN CN201280057990.1A patent/CN103958479B/zh not_active Expired - Fee Related
- 2012-09-24 CA CA2847921A patent/CA2847921A1/en active Pending
- 2012-09-24 JP JP2014531265A patent/JP6073328B2/ja not_active Expired - Fee Related
- 2012-09-24 EP EP12761636.5A patent/EP2760841B1/en active Active
- 2012-09-24 SG SG11201400403SA patent/SG11201400403SA/en unknown
- 2012-09-24 ES ES12761636.5T patent/ES2605152T3/es active Active
- 2012-09-24 AU AU2012314620A patent/AU2012314620B2/en not_active Ceased
- 2012-09-24 WO PCT/EP2012/068786 patent/WO2013045400A1/en active Application Filing
- 2012-09-24 BR BR112014007193A patent/BR112014007193A2/pt not_active IP Right Cessation
- 2012-09-24 RU RU2014117035A patent/RU2621037C2/ru not_active IP Right Cessation
- 2012-09-24 MX MX2014003675A patent/MX2014003675A/es unknown
- 2012-09-24 KR KR1020147011148A patent/KR20140082743A/ko not_active Application Discontinuation
- 2012-09-25 AR ARP120103515A patent/AR088000A1/es unknown
- 2012-09-26 TW TW101135394A patent/TWI527815B/zh not_active IP Right Cessation
- 2012-09-26 UY UY0001034350A patent/UY34350A/es not_active Application Discontinuation
-
2013
- 2013-08-02 HK HK13109032.6A patent/HK1181763A1/xx not_active IP Right Cessation
-
2014
- 2014-03-06 IL IL231386A patent/IL231386A/en not_active IP Right Cessation
-
2015
- 2015-01-09 HR HRP20150024AT patent/HRP20150024T1/hr unknown
- 2015-01-15 CY CY20151100034T patent/CY1115945T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
PT2573073E (pt) | 2015-02-05 |
ES2527188T3 (es) | 2015-01-21 |
HK1181763A1 (en) | 2013-11-15 |
HRP20150024T1 (hr) | 2015-02-13 |
AR088000A1 (es) | 2014-04-30 |
CN103958479B (zh) | 2017-06-13 |
MX2014003675A (es) | 2014-08-21 |
AU2012314620B2 (en) | 2017-06-29 |
IL231386A (en) | 2016-04-21 |
JP2014526545A (ja) | 2014-10-06 |
JP6073328B2 (ja) | 2017-02-01 |
DK2573073T3 (en) | 2015-01-19 |
RU2621037C2 (ru) | 2017-05-31 |
EP2760841B1 (en) | 2016-08-24 |
TWI527815B (zh) | 2016-04-01 |
EP2573073A1 (en) | 2013-03-27 |
BR112014007193A2 (pt) | 2017-04-04 |
SI2573073T1 (sl) | 2015-02-27 |
CY1115945T1 (el) | 2017-01-25 |
CA2847921A1 (en) | 2013-04-04 |
SG11201400403SA (en) | 2014-08-28 |
KR20140082743A (ko) | 2014-07-02 |
IL231386A0 (en) | 2014-04-30 |
PL2573073T3 (pl) | 2015-04-30 |
AU2012314620A1 (en) | 2014-03-27 |
WO2013045400A1 (en) | 2013-04-04 |
CN103958479A (zh) | 2014-07-30 |
EP2573073B1 (en) | 2014-10-22 |
RU2014117035A (ru) | 2015-11-10 |
EP2760841A1 (en) | 2014-08-06 |
TW201313719A (zh) | 2013-04-01 |
ES2605152T3 (es) | 2017-03-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY34350A (es) | Derivados de pirazolquinolinona, su preparación y su uso terapéutico. | |
UY34342A (es) | ?derivados de pirrolopirimidina y purina?. | |
UY34306A (es) | Pirimidinas condensadas sustituidas y su uso | |
ECSP17016797A (es) | Indazoles sustituidos con benzilo como inhibidores de bub1 | |
CL2013000016A1 (es) | Compuestos derivados de imidazopiridina; procedimiento de preparacion; composicion farmaceutica y su uso en el tratamiento del cancer. | |
UY34602A (es) | ?Derivados de bencimidazolil- e imidazopiridinil-metilamina? | |
UY34220A (es) | Indazoles, composiciones farmacéuticas y uso de los mismos | |
UY34764A (es) | Derivados de 2,2-difluoropropionamida de metilo de bardoxolona, formas polimórficas y sus métodos de uso | |
CR20150524A (es) | Compuestos de heteroarilo y sus usos | |
UY34314A (es) | Derivados de anilina, su preparación y su aplicación terapéutica. | |
AR089993A1 (es) | Macrociclos peptidomimeticos | |
UY34278A (es) | Derivados novedosos de oxazina y su uso en el tratamiento de enfermedades | |
MX2016008448A (es) | Conjugados de var2csa-farmaco. | |
UY33946A (es) | Derivados de c4-monometil triterpenoides y sus métodos de uso | |
MX2019002979A (es) | Formulaciones de anticuerpos. | |
BR112013021134A2 (pt) | moduladores e métodos de uso | |
UA107822C2 (en) | Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor. | |
UY34484A (es) | Benzotienilo-pirrolotriazinas disustituidas y sus usos | |
CL2013000018A1 (es) | Compuestos derivados de indolizina , su procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer, entre otros. | |
GT201200321A (es) | Derivados de heteroaril imidazolona como inhibidores de jak | |
UY34200A (es) | 3-(fluorovinil)pirazoles y su uso | |
CL2012003075A1 (es) | Composicion farmaceutica en solucion de pazopanib, estable y para uso oftalmico; metodo para la preparacion de dicha solucion. | |
CO7000778A2 (es) | Derivados de pirazolopiridina, su procedimiento de preparación y su uso terapéutico | |
UY34018A (es) | Derivados glucósidos y usos de los mismos | |
UY34725A (es) | Nuevos derivados de tienopirimidina, procesos para su preparación y sus usos terapéuticos. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20201020 |